Conduct a prospective randomized clinical study on the efficacy and safety of computer modeling for optimal AAD selection in patients with recurrent AF after catheter ablation and evaluate the efficacy and safety of AAD simulations by comparing virtual AAD effect guided therapy and empirical AAD use in patients with recurrent AF after AF catheterization.

Clinical usefulness of virtual antiarrhythmic drug test in patients with recurred AF after catheter ablation (CUVIA-AF3)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008847

Enrollment

300

Registered

2023-10-06

Start date

2023-06-13

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Conduct a prospective randomized clinical study on the efficacy and safety of computer modeling for optimal AAD selection in patients with recurrent AF after catheter ablation and evaluate the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients with 20~80 years old those recurred AF after catheter ablation 2. Patients who are suitable for sinus rhythm conversion and maintenance using AAD medications 3. Patients who had no history of serious side effects due to AAD medications before the procedure

Exclusion criteria

Exclusion criteria: 1. Permanent AF Patients 2. AF associated with significant structural heart disease with severe anomaly or hemodynamic effects 3. Patients expected to have serious side effects when using AAD due to sinus node dysfunction 4. Severe liver or renal failure 5. Patients with past cardiac surgery history 6. Patients who are unable to oral medication or have electrolyte abnormalities 7. Patients with active internal bleeding 8. Contraindications for anticoagulant therapy (administered anticoagulant drugs to prevent cerebral infarction) or AAD 9. Valvular AF (mitral stenosis> grade 2, mechanical valve, mitral valve repair) 10. Severe concomitant illness 11. Patients expected to live for less than one year 12. Patients with drug or alcoholism 13. Those who cannot read the agreement (literacy, foreigners, etc.) 14. Patients judged to be inappropriate for participation in clinical trials by other researchers' judgment

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation or atrial tachycardia > 30 sec after medication within 2 year. 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms;Major cardiovascular event rate after medication - Death, Hospitalization, Systemic embolism related atrial fibrillation, Cerebrovascular disease, Stroke, Hemorrhage	—

Measure

Time frame

Atrial fibrillation or atrial tachycardia > 30 sec after medication within 2 year. 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms;Major cardiovascular event rate after medication - Death, Hospitalization, Systemic embolism related atrial fibrillation, Cerebrovascular disease, Stroke, Hemorrhage

—

Secondary

Measure	Time frame
Comparison of cardioversion frequency, re-ablation(RFCA) and rate of re-hospitalization after medication(including re-hospitalization for complication by heart failure, embolism and hemorrhage) ;Frequency of drug complication after medication and Rate of discontinuation of medication due to complication	—

Countries

Korea, Republic of

Contacts

Public ContactSuah Lee

Yonsei University Health System, Severance Hospital

suah98@yuhs.ac+82-2-2228-8528

Outcome results